Daily Cardiology Research Analysis
Today’s most impactful cardiology research spans risk prediction, therapeutics, and real‑world care. External validation in MESA shows AHA’s PREVENT-ASCVD equations calibrate substantially better than PCE, while a phase 3 NEJM trial of the GLP-1/glucagon dual agonist mazdutide achieved 11–14% weight loss with broad cardiometabolic gains. A nationwide Medicare analysis reveals that worsening heart failure events carry high mortality and reduced home-time regardless of care setting, with nuanced c
Summary
Today’s most impactful cardiology research spans risk prediction, therapeutics, and real‑world care. External validation in MESA shows AHA’s PREVENT-ASCVD equations calibrate substantially better than PCE, while a phase 3 NEJM trial of the GLP-1/glucagon dual agonist mazdutide achieved 11–14% weight loss with broad cardiometabolic gains. A nationwide Medicare analysis reveals that worsening heart failure events carry high mortality and reduced home-time regardless of care setting, with nuanced cost tradeoffs.
Research Themes
- Risk prediction and calibration for ASCVD and HF
- Cardiometabolic pharmacotherapy for obesity
- Real-world outcomes, home-time, and costs in worsening heart failure
Selected Articles
1. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
In a phase 3, double-blind RCT of 610 adults with overweight/obesity, once‑weekly mazdutide 4 or 6 mg produced −11.0% to −14.0% mean weight loss at 48 weeks, with 35.7–49.5% achieving ≥15% weight reduction. Cardiometabolic measures improved broadly, and gastrointestinal adverse events were mostly mild-to-moderate with low discontinuation rates.
Impact: Demonstrates robust, clinically meaningful weight loss and cardiometabolic benefits with a novel GLP‑1/glucagon dual agonist, informing obesity management with potential downstream cardiovascular risk reduction.
Clinical Implications: Mazdutide could expand pharmacologic options for obesity in cardiometabolic care, potentially enabling greater weight loss than traditional monotherapies and improving BP, lipids, and glycemia; long-term CV outcome data will be essential for guideline integration.
Key Findings
- At 48 weeks, mean weight change was −11.00% (4 mg) and −14.01% (6 mg) vs 0.30% with placebo.
- At week 32, ≥5% weight loss occurred in 73.9% (4 mg) and 82.0% (6 mg) vs 10.5% with placebo; ≥15% at week 48 in 35.7% and 49.5% vs 2.0%.
- Cardiometabolic measures improved across all prespecified endpoints; GI adverse events predominated and were mostly mild-to-moderate with low discontinuation.
Methodological Strengths
- Phase 3, double-blind, randomized, placebo-controlled design with prespecified estimands
- Adequate sample size (n=610) and registered trial (NCT05607680)
Limitations
- Single-country (China) population may limit global generalizability
- 48-week duration without adjudicated cardiovascular outcomes limits inference on hard endpoints
Future Directions: Conduct multi-ethnic, longer-term outcome trials to evaluate cardiovascular and renal endpoints, durability of weight loss, and comparative effectiveness vs other incretin-based agents.
BACKGROUND: Evidence suggests that incretin-based dual agonist pharmacotherapy is helpful in persons with obesity. Mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, may have efficacy in persons with overweight or obesity. METHODS: In a phase 3, double-blind, placebo-controlled trial in China, we randomly assigned, in a 1:1:1 ratio, adults 18 to 75 years of age who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 28 or had a BMI of 24 to less than 28 plus at least one weight-related coexisting condition to receive 4 mg of mazdutide, 6 mg of mazdutide, or placebo for 48 weeks. The two primary end points were the percentage change in body weight from baseline and a weight reduction of at least 5% at week 32, as assessed in a treatment-policy estimand analysis (which assessed effects regardless of early discontinuation of mazdutide or placebo and the initiation of new antiobesity therapies). RESULTS: Among 610 participants, the mean body weight was 87.2 kg and the mean BMI was 31.1 at baseline. At week 32, the mean percentage change in body weight from baseline was -10.09% (95% confidence interval [CI], -11.15 to -9.04) in the 4-mg mazdutide group, -12.55% (95% CI, -13.64 to -11.45) in the 6-mg mazdutide group, and 0.45% (95% CI, -0.61 to 1.52) in the placebo group, and 73.9%, 82.0%, and 10.5% of the participants, respectively, had a weight reduction of at least 5% (P<0.001 for all comparisons with placebo). At week 48, the mean percentage change in body weight from baseline was -11.00% (95% CI, -12.27 to -9.73) in the 4-mg mazdutide group, -14.01% (95% CI, -15.36 to -12.66) in the 6-mg mazdutide group, and 0.30% (95% CI, -0.98 to 1.58) in the placebo group, and 35.7%, 49.5%, and 2.0% of the participants, respectively, had a weight reduction of at least 15% (P<0.001 for all comparisons with placebo). Beneficial effects on all prespecified cardiometabolic measures were seen with mazdutide. The most frequently reported adverse events were gastrointestinal and mostly mild to moderate in severity. The incidence of adverse events leading to discontinuation of the trial regimen was 1.5% with the 4-mg mazdutide dose, 0.5% with the 6-mg mazdutide dose, and 1.0% with placebo. CONCLUSIONS: In Chinese adults with overweight or obesity, once-weekly mazdutide at a dose of 4 mg or 6 mg for 32 weeks led to clinically relevant reductions in body weight. (Funded by Innovent Biologics; GLORY-1 ClinicalTrials.gov number, NCT05607680.).
2. PREVENT Risk Score vs the Pooled Cohort Equations in MESA.
In MESA (n=6,098), PREVENT-ASCVD showed superior calibration to PCE: observed 10‑year ASCVD events (6.0%) closely matched PREVENT predictions (5.7%) versus PCE (10.8%). PREVENT particularly improved accuracy in women, nonsmokers, CKD stage 3/4, socially deprived, and Black individuals, but PREVENT‑HF overestimated incident HF by 62.6% relative.
Impact: Risk prediction tools guide preventive therapy; this study provides independent, multi-ethnic validation that PREVENT-ASCVD outperforms PCE and materially reclassifies risk.
Clinical Implications: Clinicians may consider adopting PREVENT-ASCVD for 10-year ASCVD risk estimation, especially in women, nonsmokers, CKD, and socially deprived or Black populations; caution is warranted using PREVENT-HF due to overestimation.
Key Findings
- Observed 10-year ASCVD rate (6.0%) aligned with PREVENT (5.7%) but not PCE (10.8%).
- PREVENT accuracy was notably better in women, nonsmokers, CKD stage 3/4, high social deprivation, and Black individuals.
- Using PREVENT would reclassify 42% to a lower ASCVD risk category; PREVENT-HF overestimated incident HF by 2.1% (relative 62.6%).
Methodological Strengths
- External validation in a well-characterized, multi-ethnic cohort (MESA)
- Comprehensive assessment of discrimination and calibration with subgroup analyses
Limitations
- Observational analysis; residual confounding and model transportability limits remain
- PREVENT-HF miscalibration indicates need for refinement before clinical adoption
Future Directions: Prospective impact analyses on treatment decisions and outcomes across health systems; recalibration or redevelopment of PREVENT-HF for diverse cohorts.
BACKGROUND: In 2023, the American Heart Association developed the PREVENT (Predicting Risk of CVD Events) equations to estimate risk of atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF). OBJECTIVES: Assess the comparative performance of PREVENT-ASCVD vs current guideline-recommended Pooled Cohort Equations (PCE). Evaluate the performance of the PREVENT-HF risk algorithm. METHODS: In 6,098 individuals from the MESA (Multi-Ethnic Study of Atherosclerosis) cohort, we calculated baseline PCE, and PREVENT predicted 10-year ASCVD event percentages, observed event percentages at 10 years, discordance between observed and expected percentages, discrimination using Harrell's C index, and calibration using mean absolute error. RESULTS: Observed ASCVD event rate (6.0%) was closer to the predicted PREVENT event rate (5.7%) than the PCE (10.8%). PREVENT was more accurate in women than men (3.3% vs -11.6% discordance between observed and PREVENT predicted ASCVD), nonsmokers compared to smokers (2.4% vs -37.0% discordance), chronic kidney disease stages 3/4 (discordance 3.2%), and those with high social deprivation scores (discordance -5.0%). Forty-two percent of this cohort would be re-classified to a lower ASCVD risk category using the PREVENT equation vs the PCE. PREVENT-HF overestimates HF events by 2.1%, a relative risk overestimation of 62.6%. CONCLUSIONS: PREVENT-ASCVD equations demonstrated a more accurate ASCVD risk-prediction stratification than the PCE. PREVENT performs best in women, nonsmokers, those with a greater degree of renal dysfunction, social deprivation, and Black individuals. PREVENT-HF overestimates risk of incident HF in a Multi-Ethnic Study of Atherosclerosis.
3. Clinical and financial implications of inpatient and outpatient management of worsening heart failure.
Among 181,827 older HF patients, 61,159 had WHF within 12 months. Mortality and home-time were worst after HF hospitalization (12-month mortality IR 48.8; lowest home-time), with observation stays faring best. Although outpatient IV diuretics had the lowest index event cost, 12‑month cumulative costs were similar to or higher than hospitalization.
Impact: Provides large-scale, real-world evidence linking WHF care settings to mortality, home-time, and costs, informing system-level strategies and resource allocation.
Clinical Implications: Preventing WHF and optimizing guideline-directed medical therapy remain paramount; observation pathways may preserve home-time, while outpatient IV diuretic strategies require careful selection and follow-up given comparable 12‑month costs and outcomes.
Key Findings
- Of 61,159 WHF events, management was HF hospitalization 79.5%, ED discharge 13.3%, observation stay 2.9%, outpatient IV diuretic 4.3%.
- 12‑month mortality was highest after HF hospitalization (IR 48.8) and lowest after observation stays (IR 29.9); home-time mirrored these differences.
- Index WHF costs were lowest for outpatient IV diuretics, but 12‑month total costs were similar or higher vs hospitalization, especially when including decedents.
Methodological Strengths
- Linkage of GWTG‑HF registry to Medicare claims across 553 hospitals with large sample size
- Patient-centered metrics including home-time and comprehensive cost analyses
Limitations
- Observational design with potential residual confounding and coding misclassification
- Findings may not generalize beyond older Medicare beneficiaries or non‑US systems
Future Directions: Prospective evaluations of WHF care pathways optimizing mortality, home-time, and cost; identification of phenotypes best suited for observation or outpatient IV diuresis.
AIMS: Little is known regarding the clinical and financial implications of varying inpatient and outpatient management strategies for worsening heart failure (WHF). This analysis aimed to compare clinical outcomes, home-time, and healthcare expenditure following various types of inpatient and outpatient WHF events in US clinical practice. METHODS AND RESULTS: We examined US Medicare beneficiaries 65 years and older discharged from a hospitalization for heart failure (HF) in the Get With The Guidelines-Heart Failure registry from 2010 to 2018. Patients developing subsequent WHF within 12 months were divided into four mutually exclusive groups by type of first event: HF hospitalization, emergency department (ED) visit with ED discharge, observation stay, and outpatient intravenous (IV) diuretic clinic visit. Following each type of WHF event, mortality, home-time (days alive and out of any healthcare institution), and healthcare costs were compared over the subsequent 12 months. Among 181 827 eligible patients discharged alive from a HF hospitalization across 553 US hospitals, 61 159 (33.6%) patients had a subsequent WHF event within 12 months. Of these, 48 612 were managed with HF hospitalization (79.5%), 8139 (13.3%) with an ED visit, 1767 (2.9%) with an observation stay, and 2641 (4.3%) with an outpatient IV diuretic visit. Rates of 12-month mortality were highest following HF hospitalization (cumulative incidence rate [IR] 48.8; 95% confidence interval [CI] 48.3-49.3), lowest following observation unit stay (IR 29.9; 95% CI 27.7-32.0), and intermediate following ED discharge (IR 41.2; 95% CI 40.1-42.3) and outpatient IV diuretic visit (IR 39.3; 95% CI 37.4-41.2). Median (25th-75th) 12-month home-time was lowest following HF hospitalization (251 [47-351] days) and highest following observation unit stays (354 [206-365] days). For the index WHF event itself, median total per-patient costs were highest for HF hospitalization (US$11 335) and lowest for outpatient IV diuretic visit (US$259). Over the 12 months following the WHF event, when accounting for costs of all patients including those who died within 12 months, the median total per-patient costs were highest following outpatient IV diuretic visits (US$29 173). Among patients surviving 12 months after WHF, median total per-patient costs following an outpatient IV diuretic visit (US$29 931) versus HF hospitalization (US$30 971) were similarly high. CONCLUSIONS: In this nationwide analysis of older US adults, high rates of death and substantial reductions in home-time occurred following WHF regardless of inpatient or outpatient management, but were worse following HF hospitalization. Outpatient IV diuretic administration was the least expensive initial management strategy, but over the subsequent 12 months, associated costs were similar or higher than costs following HF hospitalization.